In the Journals Plus

Filgrastim biosimilars show ‘substantial uptake’ among Medicare beneficiaries

September 4, 2018
The use of biosimilar biologics filgrastim-sndz and tbo-filgrastim increased substantially among Medicare beneficiaries between 2014 and 2016…
In the JournalsPerspective

Infliximab biosimilar 'only moderately' less costly vs. biologic under Medicare Part D

September 4, 2018
Under Medicare Part D drug benefits, the biosimilar infliximab-dyyb was only 18% less expensive than the infliximab reference product, exceeding…
Meeting News

Education, patience key to guide biosimilar-hesitant patients through transition

August 11, 2018
FORT WORTH, Texas — Although the use of biosimilars is expected to improve patient access to biologics, open communication between providers…
Editorial

Biosimilars Safe, Effective Alternatives to Originator Biologics

July 23, 2018
As the first biosimilars are being introduced and becoming more common in the United States, it is worthwhile to understand how the approval process…
FDA News

Gottlieb: FDA will not 'play regulatory whack-a-mole' with those delaying biosimilar competition

July 19, 2018
In a statement introducing an action plan aimed at promoting competition across the drug market for biosimilar and biologic products, FDA…

Biosimilar Barriers Persist Despite Billions in Potential Cost Savings: Who is Benefitting?

July 16, 2018
Many health care researchers wake up each morning and head to the laboratory with the hope of achieving something like a promise. That promise is…
Editorial

Interchangeable Biologics as Safe, Efficacious as Non-Interchangeable Biosimilars

July 6, 2018
As biosimilars enter the United States market, there is a new vocabulary that doctors, patients and patient advocates need to learn as it is…
FDA News

FDA withdraws biosimilar draft guidance following public comments

June 21, 2018
The FDA has withdrawn a draft guidance intended to provide advice for biosimilar sponsors regarding the determination of similarity between the…

ACR releases position statement on pharmacovigilance

June 13, 2018
The American College of Rheumatology has recently issued a position statement on pharmacovigilance, highlighting the importance of monitoring new…
FDA News

FDA approves Fulphila, first Neulasta biosimilar, to prevent infection during cancer treatment

June 4, 2018
The FDA approved Fulphila, the first biosimilar to pegfilgrastim, to decrease risk for infection, as suggested by febrile neutropenia, among patients…